POMC and adrenal carcinoma: Verhelst et al. in a retrospective study evaluated ACTH patterns in patients with adrenal-dependent CS on metyrapone and did not find any significant ACTH increase in ten patients with adrenal adenoma and six patients with adrenal carcinoma (8).